

Xiaoduo Fan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9240261/publications.pdf>

Version: 2024-02-01

115
papers

3,658
citations

101384

36
h-index

161609

54
g-index

116
all docs

116
docs citations

116
times ranked

5068
citing authors

#	ARTICLE	IF	CITATIONS
1	Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 633-642.	1.8	6
2	The effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naïve, first episode schizophrenia patients. <i>Psychiatry Research</i> , 2022, 313, 114582.	1.7	12
3	A Pilot Remote Drama Therapy Program Using the Co-active Therapeutic Theater Model in People with Serious Mental Illness. <i>Community Mental Health Journal</i> , 2022, 58, 1613-1620.	1.1	2
4	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. <i>Schizophrenia Research</i> , 2021, 230, 87-94.	1.1	2
5	A narrative review of mindfulness-based therapy for schizophrenia, co-occurring substance use and comorbid cardiometabolic problems. <i>Psychiatry Research</i> , 2021, 296, 113707.	1.7	4
6	Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 244-249.	0.7	3
7	Effect of citalopram on hippocampal volume in first-episode schizophrenia: Structural MRI results from the DECIFER trial. <i>Psychiatry Research - Neuroimaging</i> , 2021, 312, 111286.	0.9	3
8	The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 724664.	1.3	14
9	Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study. <i>Translational Psychiatry</i> , 2021, 11, 422.	2.4	25
10	Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis. <i>Schizophrenia Research</i> , 2020, 215, 337-343.	1.1	24
11	Treatment and services for psychosis: Are college campuses a novel frontier for early detection and intervention?. <i>Psychiatry Research</i> , 2020, 284, 112699.	1.7	2
12	Solute Carrier Family 1 (SLC1A1) Contributes to Susceptibility and Psychopathology Symptoms of Schizophrenia in the Han Chinese Population. <i>Frontiers in Psychiatry</i> , 2020, 11, 559210.	1.3	3
13	Insulin Resistance and Oxidative Stress: In Relation to Cognitive Function and Psychopathology in Drug-Naïve, First-Episode Drug-Free Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 537280.	1.3	13
14	Dual diagnosis theater: A pilot drama therapy program for individuals with serious mental illness and substance use disorder. <i>Schizophrenia Research</i> , 2020, 230, 95-97.	1.1	3
15	The impact of COVID-19 on individuals living with serious mental illness. <i>Schizophrenia Research</i> , 2020, 222, 3-5.	1.1	61
16	Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophrenia. <i>Schizophrenia Research</i> , 2020, 222, 23-30.	1.1	11
17	Association of DTNBP1 With Schizophrenia: Findings From Two Independent Samples of Han Chinese Population. <i>Frontiers in Psychiatry</i> , 2020, 11, 446.	1.3	7
18	Air pollution and hippocampal atrophy in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 218, 63-69.	1.1	7

#	ARTICLE	IF	CITATIONS
19	The role of altered brain structural connectivity in resilience, vulnerability, and disease expression to schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 101, 109917.	2.5	6
20	Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: Structural MRI Results From the DECIFER Trial. <i>Biological Psychiatry</i> , 2020, 87, S166.	0.7	0
21	Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naïve, first-episode schizophrenia: Results from two independent study samples. <i>EBioMedicine</i> , 2019, 46, 248-255.	2.7	24
22	Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naïve, First-Episode Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 741.	1.3	20
23	Methamphetamine-associated psychosis: Clinical presentation, biological basis, and treatment options. <i>Human Psychopharmacology</i> , 2019, 34, e2710.	0.7	38
24	Pilot lifestyle education intervention for patients with severe mental illness during the inpatient stay. <i>Asian Journal of Psychiatry</i> , 2019, 40, 15-17.	0.9	4
25	Insomnia in patients with schizophrenia: current understanding and treatment options. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 235-242.	2.5	36
26	Citalopram in first episode schizophrenia: The DECIFER trial. <i>Schizophrenia Research</i> , 2019, 208, 331-337.	1.1	15
27	Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 286.	1.3	43
28	Mixed methods to explore factors associated with the decline of patients in the methadone maintenance treatment program in Shanghai, China. <i>Harm Reduction Journal</i> , 2019, 16, 34.	1.3	5
29	<p>Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1141-1150.	1.0	27
30	The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy. <i>CNS Drugs</i> , 2019, 33, 539-547.	2.7	20
31	Creative art therapy for mental illness. <i>Psychiatry Research</i> , 2019, 275, 129-136.	1.7	63
32	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 691.	6.0	18
33	Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. <i>Psychopharmacology</i> , 2019, 236, 1949-1957.	1.5	3
34	The Miniature Robotic Needling Device in Brachytherapy: Design and Modeling - An Approach Towards Smart Needle System. , 2019, , .		2
35	Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 370.	6.0	56
36	No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 125-128.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Racial disparity in mental disorder diagnosis and treatment between non-hispanic White and Asian American patients in a general hospital. <i>Asian Journal of Psychiatry</i> , 2018, 34, 78-83.	0.9	8
38	Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 199, 390-394.	1.1	10
39	Abnormal regional homogeneity as a potential imaging biomarker for adolescent-onset schizophrenia: A resting-state fMRI study and support vector machine analysis. <i>Schizophrenia Research</i> , 2018, 192, 179-184.	1.1	80
40	Gray matter volume showed dynamic alterations in methamphetamine users at 6 and 12 months abstinence: A longitudinal voxel-based morphometry study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 350-355.	2.5	19
41	Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2018, 33, 88-91.	0.9	4
42	Microglia activation in the offspring of prenatal Poly I: C exposed rats: a PET imaging and immunohistochemistry study. <i>Annals of General Psychiatry</i> , 2018, 31, e000006.	1.1	17
43	Disrupted asymmetry of inter- and intra-hemispheric functional connectivity in patients with drug-naïve, first-episode schizophrenia and their unaffected siblings. <i>EBioMedicine</i> , 2018, 36, 429-435.	2.7	32
44	Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. <i>Schizophrenia Research</i> , 2018, 201, 299-306.	1.1	112
45	Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia. <i>Frontiers in Pharmacology</i> , 2018, 9, 181.	1.6	18
46	Impaired cue identification and intention retrieval underlie prospective memory deficits in patients with first-episode schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 270-277.	1.3	12
47	Antioxidant and anti-inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 78, 1-11.	2.5	61
48	The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 465-472.	2.2	18
49	Altered resting-state intra- and inter- network functional connectivity in patients with persistent somatoform pain disorder. <i>PLoS ONE</i> , 2017, 12, e0176494.	1.1	38
50	Decreased Functional Connectivity of Insular Cortex in Drug Naïve First Episode Schizophrenia: In Relation to Symptom Severity. <i>PLoS ONE</i> , 2017, 12, e0167242.	1.1	16
51	Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 397-406.	1.0	52
52	Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 51-56.	0.9	3
53	Altered Neural Correlates of Emotion Associated Pain Processing in Persistent Somatoform Pain Disorder: An fMRI Study. <i>Pain Practice</i> , 2016, 16, 969-979.	0.9	14
54	Vitamin D in schizophrenia: a clinical review. <i>Evidence-Based Mental Health</i> , 2016, 19, 6-9.	2.2	62

#	ARTICLE	IF	CITATIONS
55	Abnormal white matter microstructure in drug-naïve first episode schizophrenia patients before and after eight weeks of antipsychotic treatment. <i>Schizophrenia Research</i> , 2016, 172, 1-8.	1.1	75
56	The Clinical Value, Principle, and Basic Practical Technique of Mindfulness Intervention. <i>Shanghai Archives of Psychiatry</i> , 2016, 28, 121-130.	0.7	6
57	Hippocampal volume reduction in female but not male recent abstinent methamphetamine users. <i>Behavioural Brain Research</i> , 2015, 289, 78-83.	1.2	22
58	Dysfunctional resting-state connectivities of brain regions with structural deficits in drug-naïve first-episode schizophrenia adolescents. <i>Schizophrenia Research</i> , 2015, 168, 353-359.	1.1	31
59	Decreased cortical thickness in drug naïve first episode schizophrenia: In relation to serum levels of BDNF. <i>Journal of Psychiatric Research</i> , 2015, 60, 22-28.	1.5	34
60	Schizophrenia and the gut-brain axis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 155-160.	2.5	110
61	Neural Correlates of the Preserved Inhibition of Return in Schizophrenia. <i>PLoS ONE</i> , 2015, 10, e0119521.	1.1	1
62	APOA-I: A Possible Novel Biomarker for Metabolic Side Effects in First Episode Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e93902.	1.1	14
63	Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. <i>Behavioral and Brain Functions</i> , 2014, 10, 35.	1.4	25
64	What Can the Medical Education Do for Eliminating Stigma and Discrimination Associated with Mental Illness among Future Doctors? Effect of Clerkship Training on Chinese Students' Attitudes. <i>International Journal of Psychiatry in Medicine</i> , 2014, 47, 241-254.	0.8	32
65	Prolactin serum levels correlate with inflammatory status in drug-naïve first-episode schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 546-552.	1.3	20
66	Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 319-325.	1.5	87
67	A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism. <i>Schizophrenia Research</i> , 2014, 159, 395-403.	1.1	51
68	Phenotypic characteristics in metabolically healthy but obese patients with schizophrenia. <i>Psychiatry Research</i> , 2014, 220, 71-75.	1.7	0
69	Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. <i>Schizophrenia Research</i> , 2014, 159, 51-55.	1.1	40
70	Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: A study of drug naïve, first-episode schizophrenia patients and unaffected siblings. <i>Schizophrenia Research</i> , 2014, 159, 43-50.	1.1	43
71	Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naïve, first-episode patients with schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 339-343.	1.1	68
72	Activation of Th17 cells in drug naïve, first episode schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 78-82.	2.5	102

#	ARTICLE	IF	CITATIONS
73	Effects of 420nm intense pulsed light in an acne animal model. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1168-1171.	1.3	19
74	Prospective memory performance in patients with drug-naïve, first-episode psychosis. <i>Schizophrenia Research</i> , 2013, 143, 285-290.	1.1	22
75	Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. <i>Schizophrenia Research</i> , 2013, 150, 269-273.	1.1	76
76	Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. <i>Psychopharmacology</i> , 2013, 225, 627-635.	1.5	31
77	Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 217-226.	2.2	46
78	No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 40-45.	1.1	14
79	Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics. <i>Evidence-Based Mental Health</i> , 2013, 16, 10-10.	2.2	4
80	Human Papillomavirus E7 Induces Rereplication in Response to DNA Damage. <i>Journal of Virology</i> , 2013, 87, 1200-1210.	1.5	30
81	No Effect of Adjunctive, Repeated-Dose Intranasal Insulin Treatment on Psychopathology and Cognition in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 226-230.	0.7	14
82	Species-specific factors mediate extensive heterogeneity of mRNA 3' ends in yeasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11073-11078.	3.3	47
83	Duration of Untreated Psychosis Is Associated with Temporal and Occipitotemporal Gray Matter Volume Decrease in Treatment Naïve Schizophrenia. <i>PLoS ONE</i> , 2013, 8, e83679.	1.1	44
84	Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: A pilot study. <i>Psychiatry Research</i> , 2012, 200, 79-82.	1.7	15
85	Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia. <i>Schizophrenia Research</i> , 2012, 140, 260-261.	1.1	12
86	Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. <i>Schizophrenia Research</i> , 2011, 130, 53-56.	1.1	18
87	Placebo-Controlled Pilot Study of Ramelteon for Adiposity and Lipids in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 653-658.	0.7	31
88	No Effect of Single-Dose Intranasal Insulin Treatment on Verbal Memory and Sustained Attention in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 231-234.	0.7	19
89	Triglyceride/High-Density Lipoprotein Cholesterol Ratio. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 806-812.	1.1	40
90	Nucleosome depletion at yeast terminators is not intrinsic and can occur by a transcriptional mechanism linked to 3' end formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17945-17950.	3.3	79

#	ARTICLE	IF	CITATIONS
91	Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. <i>Schizophrenia Research</i> , 2010, 118, 211-217.	1.1	72
92	Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia. <i>Schizophrenia Research</i> , 2010, 124, 49-53.	1.1	7
93	Deficient inhibition of return in chronic but not first-episode patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 961-967.	2.5	7
94	Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). <i>Psychiatry Research</i> , 2010, 176, 99-102.	1.7	42
95	Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. <i>Annals of Clinical Psychiatry</i> , 2010, 22, 33-42.	0.6	16
96	Ziprasidone as an adjuvant for clozapine or olanzapine-associated medical morbidity in chronic schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 225-232.	0.7	19
97	A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 457-465.	2.2	38
98	Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 165-169.	0.7	79
99	Waist Circumference is the Best Anthropometric Predictor for Insulin Resistance in Nondiabetic Patients with Schizophrenia Treated with Clozapine but not Olanzapine. <i>Journal of Psychiatric Practice</i> , 2009, 15, 251-261.	0.3	19
100	Modafinil for Clozapine-Treated Schizophrenia Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1674-1680.	1.1	70
101	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. <i>Psychiatry Research</i> , 2008, 159, 140-146.	1.7	49
102	Race Moderates Age-Related Cognitive Decline in Type 2 Diabetes. <i>Experimental Aging Research</i> , 2008, 34, 114-125.	0.6	8
103	Light to Moderate Alcohol Drinking is Associated with Higher Cognitive Function in Males with Type 2 Diabetes. <i>Experimental Aging Research</i> , 2008, 34, 126-137.	0.6	5
104	Waist circumference does not predict insulin resistance in African American schizophrenia patients. <i>International Journal of Culture and Mental Health</i> , 2008, 1, 93-104.	0.6	1
105	Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. <i>Psychiatry Research</i> , 2007, 149, 267-271.	1.7	138
106	Sexual functioning, psychopathology and quality of life in patients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 94, 119-127.	1.1	60
107	Inflammation and schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 789-796.	1.4	106
108	A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 101-105.	2.2	50

#	ARTICLE	IF	CITATIONS
109	Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 533-541.	1.1	79
110	Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients. <i>Biological Psychiatry</i> , 2006, 60, 1372-1377.	0.7	10
111	Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. <i>Schizophrenia Research</i> , 2006, 86, 30-35.	1.1	21
112	Ultrasound surgery using multiple sonicationsâ€”Treatment time considerations. <i>Ultrasound in Medicine and Biology</i> , 1996, 22, 471-482.	0.7	151
113	A study of various parameters of spherically curved phased arrays for noninvasive ultrasound surgery. <i>Physics in Medicine and Biology</i> , 1996, 41, 591-608.	1.6	60
114	Control of the necrosed tissue volume during noninvasive ultrasound surgery using a 16-element phased array. <i>Medical Physics</i> , 1995, 22, 297-306.	1.6	67
115	Walking together: Exploring perspectives, attitudes, and barriers on nutrition and exercise among individuals with serious mental illness. <i>Current Psychology</i> , 0, , 1.	1.7	0